IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: Hayes, Robert Clinton
Kevin P. BAKER, et al.	Art Unit: 1647
Application Serial No. 10/015,499	Confirmation No. 6886
Filed: December 11, 2001	Attorney's Docket No. 39780-2830 P1C42
For: PRO1788 POLYPEPTIDES)	Customer No. 35489

EXPRESS MAIL LABEL NO. <u>EV 765 979 634 US</u> DATE MAILED: AUGUST 11, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\boxtimes	This sta	itement qualifie	s under 37 C.F.R. §1.97, subsection (b) because (check all that apply):	
		(1) than a	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR	
		(2)	It is being filed within 3 months of entry of a national stage OR	
		(3) merits	It is being filed before the mail date of the first Office Action on the	
	\boxtimes	(4) of a re	OR It is being filed before the mailing of a first Office Action after the filing quest for continued examination under § 1.114.	
37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyon filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first C action on the merits, but before the mailing date of the earlier of a final office action under § or a notice of allowance under §1.311, then:				
		a certification	as specified in §1.97(e) is provided below; or	
			other papers filed together with this statement.	
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a f office action under §1.113 or a notice of allowance under §1.311, but before payment of the fee, then:			
٠	A.	a certification	as specified in §1.97(e) is completed below; and	
	В.	a petition unde submitted here	r 37 C.F.R. §1.97(d) requesting consideration of this statement is with; and	
	C.		0 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with other papers filed together with this statement.	
	of \$0.0	<u>0</u> and charge ar	e Commissioner is hereby authorized to charge the above-referenced fees y additional fees or credit any overpayment associated with this osit Account No. <u>08-1641 (Attorney's Docket No. 39780-2830 P1C42)</u> .	
			Respectfully submitted,	
Dated:	August	11, 2006	By:	
DIET I	ro ren	DMANIID		

275 Middlefield Road

Menlo Park, California 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

AUG 1 1 2006 &

2 2 2000	<i>y</i>)	Form PTO-	1449	Attorney's Docket No.			ication Seria	l No.	91,000
SUPENING PRINCIPLE STATEMENT		39780-2830 P1C42 Applicant(s)	39780-2830 P1C42 10/015,499 Applicant(s)						
	-				Kevin P. BAKE	ΞR,e	t al.		
	luco con	voral choote	if necessary)	Filing Date: DECEMBER 11, 2001		Grou 1647	p Art Unit:		_
<u> </u>	(use sev	erai Sileets		U.S. PATENT DOCUMENTS	<u></u>	1047			
Examiner	Ref.	Date	Document No.	Name		ass	Subclass	Filing Date	
Initials	No.	Juio	Booumone ito.	, valing	J			(if appropri	
		1		REIGN PATENT DOCUMEN					
Examiner	Ref.	Date	Document No.	Name	Cla	ass	Subclass	Transla	
Initials	No.							YES	NO
	<u> </u>	<u>I</u>	1	OTHER DOCUMENTS				L	L
			(including	author, title, date, pertinent p	ages, etc.)				
Examiner	Ref.	Title			*				
Initials	No.								
	1.			-Mobility Group A2 Expression Cancer - 89(11):2104-9 (2003)		ed wit	th malignant	Phenotype i	n
	2.	Ando, M., et al., "Selective Apoptosis of Natural Killer-Cell Tumours by I-Asparaginase," Br J Haematol., - 130(6):860-8 (2005) Abstract.							
	1			arcinoma Cell Lines and Norm	nal Thyrocytes: Exp	ressi	on and Regu	lation of Mat	rix
	3.			senger-RNA and Protein," Thy					
	4.		Barnes, V.L., et al., " Expression of Embryonic Fibronectin Isoform EllIA Parallels Alpha-Smooth Muscle Actin in Maturing and Diseased Kidney," J Histochem Cytochem 47(6):787-98 (1999) Abstract.						
	5.	Bea, S., et al., "BMI-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle Cell Lymphonas," Cancer Res 61(6):2409-12 (2001) Abstract.							
	6.	Blaschke, V., et al., "Rapid Quantitation of Proinflammatory and Chemoattractant Cytokine Expression in Small Tissue Samples and Monocyte-Derived Dendritic Cells: Validation of a New Real-Time RT-PCR Technology," <i>J Immunol Methods</i> 246(1-2):79-90 (2000) Abstract.							
	7.	Buckley, A.R., et al., "Butyrate-Induced Reversal of Dexamethasone Resistance in Autonomouse Rat Nb2 Lymphoma Cells," Apoptosis 2(6):518-28 (1997) Abstract.				oma			
	8.	Caberlotto,	L. et al.,"Alterations in	Neuropeptide Y Levels and Y ion," Neurosci Lett 265(3):19			nders Sensi	tive Line Rat	s, A
	9.	Caberlotto, L., et al., "Neurokinin 1 Receptor and Relative Abundance of the Short and Long Isoforms in the Human				an			
	J		J Neurosci 17(9):173						
	10.	Choi, D., et al., "Characterization of Cyclin D2 Expression in Human Endometrium," J Soc Gynecol Investig 9(1):41-6 (2002) Abstract.							
	11.		A., et al., "Human Cho (3):279-84 (2004) Abstr	rionic Gonadotrophin Beta Expact.	pression in Maligna	ant Ba	rrett's Oeso	phagus," <i>Vir</i>	chows
	12.	Dagenais, A	A., et al., "Downregulat	ion of EnaC Activity and Expre 86(2):L301-11 (2004) Abstract.	•	na in A	Alveolar Epit	helial Cells,"	Am J.
	13.			of the CCNDI Gene in Hairy Ce		Onco	<i>l <u>7(3</u>):251-</i>	6 (1996) Abs	tract.
	14.		, et al., "Inhibin and Ac eprod <u>6(8)</u> :743-9 (200	tivin Production and Subunit I	Expression in Huma	an Pla	cental Cells	Cultured in	Vitro,"
	15.	Dong, Z., et	al., "Expression of Me	embrane-Type Matrix Metallopi s Sci - 42(13):3223- (2001) Abs		l 6 in l	Mouse Corn	eas Infected	with P.

CVALINE	
EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conf	orms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next of	communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2226418 v1

Form PTO-1449

Sheet 2 of 8 Attorney's Docket No. Application Serial No. 10/015.499 39780-2830 P1C42 Applicant(s) RMATION DISCLOSURE STATEMENT Kevin P. BAKER, et al. **Group Art Unit:** Filing Date: (use several sheets if necessary) **DECEMBER 11, 2001** 1647 OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Duchrow, M., et al., "Assessment of Proliferative Activity in Colorectal Carcinomas by Quantitative Reverse 16. Transcriptase-Polymerase Chain Reaction (RT-PCR)," Cancer Invest. - 19(6):588-96 (2001) Abstract. Dyer, J., et al., "Molecular Characterisation of Carbohydrate Digestion and Absorption in Equine Small Intestine," 17. Equine Vet J. - 34(4):349-58 (2002) Abstract. Egwuagu, C.E., et al., "Suppressors of Cytokine Signaling Proteins are Differentially Expressed in Th1 and Th2 Cells: 18. Implications for Th Cell Lineage Commitment and Maintenance," J Immunol. - 168(7):3181-7 (2002) Abstract. El-Ghrably, I.A., et al., "Intravitreal Invading Cells Contribute to Vitreal Cytokine Milieu in Proliferative 19. Vitreoretinopathy," Br J Opthalmol. - 85(4):461-70 (2001) Abstract. Eleore, L., et al., "Modulation of the Glutamatergic Receptors (AMPA and NMDA) and of Glutamate Vesicular 20. Transporter 2 in the Rat Facial Nucleus after Axotomy," Neuroscience - 136(1):147-60 (2005) Abstract. Forsberg, H., et al., "Altered Levels of Scavenging Enzymes in Embryos Subjected to a Diabetic Environment," Free 21. Radic Res. - 24(6):451-9 (1996) Abstract. Freyschuss, B., et al., "Induction of the Estrogen Receptor by Growth Hormone and Glucocorticoid Substitution in 22. Priminary Cultures of Rat Hepatocytes," Endocrinology - 133(4):1548-54 (1993) Abstract. Fu, K., et al., "Cyclin D1-Negative Mantle Cell Lymphoma: A Clinocopathologic Study Based on Gene Expression 23. Profiling," Blood - 106(13):4315-21 (2005) Abstract. Fuchs, A.R., et al., "Oxytocin Receptors in Bovine Cervix: Distrubution and Gene Expression During the Estrous 24. Cycle," Biol Reprod. - 54(3):700-8 (1996) Abstract. Furuta, J., et al., "Silencing of the Thrombomodulin Gene in Human Malignant Melanoma," Melanoma Res. - 15(1):15-20 25. (2005) Abstract. Futcher, B., et al., "A Sampling of the Yeast Proteome," Mol Cell Biol., - 19(11):7357-68 (1999) Abstract. 26. George, J., et al., "Pre-translational Regulation of Cytochrome P450 Genes is Responsible for Disease-Specific 27. Changes of Individual P450 Enzymes Among Patients with Cirrhosis," Biochem Pharmacol. - 49(7):873-81 (1995) Abstract. Giroux, M., et al., "Cyclooxygenase-2 Expression in Macrophages: Modulation by Protein Kinase C-alpha," J immunol. -28. 165(7):3985-91 (2000) Abstract. Gnatenko, D.V., et al., "Transcript Profiling of Human Platelets Using Microarray and Serial Analysis of Gene 29. Expression," Blood - 101(6):2285-93 (2003) Abstract. Godbout, R., et al., "Overexpression of DEAD Box Protein (DDX1) in Neuroblastoma and Retinoblastoma Cell Lines," J 30. Biol Chem, - 273(33):21161-8 (1998) Abstract. Goldenberg, R.C., et al., "Modulation of Gap Junction Mediated Intercellular Communication in TM3 Leydig Cells," J 31. Endocrinol. - 177(2):327-35 (2003) Abstract. Golebiowski, F., et al., "Expression Level of Ubc9 Protein in Rat Tissues," Acta Biochim Pol. - 50(4):1065-73 (2003) 32. Grem, J.L., et al., "Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell 33. Lines of the National Cancer Institute's Anticancer Drug Screen," Clin Cancer Res. - 7(4):999-1009 (2001) Abstract. Grenback, E., et al., "Galanin Pituitary Adenomas," Regul Pept, - 117(2):127-39 (2004) Abstract.

EXAMINER:	DATE CONSIDERED:
	DATE CONCIDENCES.

Gromova, I., et al., "Protein Abundance and mRNA Levels of the Adipocyte-Type Fatty Acid Binding Protein Correlate in

Non-Invasive and Invasive Bladder Transitional Cell Carcinomas," Int J. Oncol. - 13(2):379-83 (1998) Abstract. Guo, Y., et al., "The Pathogenic Role of Macrophage Migration Inhibitory Factor in Acute Respiratory Distress

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Syndrome," Zhinghua Jie He He Hu Xi Za Zhi - 25(6):337-40 (2002) Abstract.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2226418 v1

34.

35.

36.

PTO/SB/08 (2/92) Sheet 3 of 8 Form PTO-1449 Attorney's Docket No. **Application Serial No.** 10/015,499 39780-2830 P1C42 MATION DISCLOSURE STATEMENT Applicant(s) Kevin P. BAKER, et al. **Group Art Unit:** Filing Date: 1647 (use several sheets if necessary) **DECEMBER 11, 2001** OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Habu, Y., et al., "Restored Expression and Activity of Organic Ion Transporters rOAT1, rOAT3 and rOCT2 after 37. Hyperuricemia in the Rat Kidney," Biochem Pharmacol - 69(6):993-9 (2005) Abstract. Hahn, M.E., et al., "Regulation of Cytochrome P4501A1 in Teleosts: Sustained Induction of CYP1A1 mRNA, Protein, and Catalytic Activity by 2,3,7,8-Tetrachlorodibenzofuran in the Marine Fish Stenotomus Chrysops," Toxicol Appl 38. Pharmacol. - 127(2):187-98 (1994) Abstract. Hahnel, R., et al., "Expression of the pS2 Gene in Breast Tissues Assessed by pS2-mRNA Analysis and pS2-Protein 39. Radioimmunoassay," Breast Cancer Res Treat. - 24(1):71-4 (1992) Abstract. Hamilton, L.M., et al., "The role of the Epidermal Growth Factor Receptor in Sustaining Neutrophil Inflammation in 40. Severe Asthma," Clin Exp Allergy. - 33(2):233-40 (2003) Abstract. Hassett, C., et al., "Human Hepatic Microsomal Epoxide Hydrolase: Comparative Analysis of Polymorphic Expression," 41. Arch Biochem Biophys. - 337(2):275-83 (1997) Abstract. Holten-Andersen, M.N., et al., "Localization of Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) in Human Colorectal 42. Adenoma and Adenocarcinoma," Int J Cance, - 113(2):198-206 (2005) Abstract. Huang, Y.H., et al., "Tissue Plasminogen Activator Induced by Dengue Virus Infection of Human Endothelial Cells," J 43. Med Virol. - 70(4):610-6 (2003) Abstract. Huettner, P.C., et al., "Neu Oncogene Expression in Ovarian Tumors: A Quantitative Study," Mod Pathol. - 5(3):250-6 44. (1992) Abstract. Hui, P., et al., "Real-time Quantitative RT-PCR of Cyclin D1 mRNA in Mantle Cell Lymphoma: Comparison with FISH and 45. Immunohistochemistry," Leuk Lymphoma. 44(8):1385-94 (2003) Abstract. Husain, I., et al., "Elevation of Topoisomerase I Messenger RNA, Protein, and Catalytic Activity in Human Tumors: Demonstration of Tumor-Type Specificity and Implications for Cancer Chemotherapy," Cancer Res. - 54(2):539-46 46. (1994) Abstract. Ihmann, T., et al., "High-level mRNA Quantification of Proliferation Marker pKi-67 is Correlated with Favorable 47. Prognosis in Colorectal Carcinoma," J Cancer Res Clin Oncol. - 130(12):749-56 (2004) Abstract. Ikegami, T., et al., "Modulation of Glucagon Receptor Expression and Response in Transfected Human Embryonic 48. Kidney Cells," Am J Physiol Cell Physiol. - 281(4):C1396-402 (2001) Abstract. Jacquemin, E., et al., "Developmental Regulation of Acidic Fibroblast Growth Factor (aFGF) Expression in Bovine 49. Retina," Int J Biol. - 37(3):417-23 (1993) Abstract. Jaime, M., et al., "The p21 (Cip1) Protein, A Cyclin Inhibitor, Regulates the Levels and the Intracellular Localization of 50. CDC25A in Mice Regenerating Livers," Hepatology - 35(5):1063-71 (2002) Abstract. Janssens, N., et al., "Alteration of Frizzled Expression in renal Cell Carcinoma," Tumour Biol. - 25(4):161-71 (2004) 51. Abstract. Jungbluth, A.A., et al., "Immunohistochemical Analysis of NY-ESO-1 Antigen Expression in Normal and Malignant 52. Human Tissues," Int J. Cancer - 92(6):856-60 (2001) Abstract. Kalabis, G.M., et al., "Multidrug Resistance Phosphoglycoprotein (ABCB1) in the Mouse Placenta: Fetal Protection,"

	56.	Int J. Biochem Cell Biol 37(10):2196-206 (2005) Abstract.		
EXAMINER: DATE CONSIDERED:				

Biol Reprod. - 73(4):591-7 (2005) Abstract.

J Cancer - 93(7):774-80 (2005), Abstract.

27(5):1257-63 (2005) Abstract.

53.

54.

55.

56.

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2226418 v1

Kammaori, M., et al., "Expression of Human Telomerase Reverse Transcriptase Gene and Protein, and of Estrogen amd

Khal, J., et al., "Expression of the Ubiquitin-Proteasome Pathway and Muscle Loss in Experimental Cancer Cachexi," Br

Khal, J., et al., "Increased Expression of Proteasome Subunits in Skeletal Muscle of Cancer Patients with Weight Loss,"

Progesterone Receptors, in Breast Tumors: Preliminary Data from Neo-Adjuvant Chemotherapy," Int J Oncol. -

AUG 1 1 2005 %

يرا Form PTO-1449		Form PTO-1449	39780-2830 P1C42	Application Serial No. 10/015,499	
Company Departs	PERSONATION DISCLOSURE STATEMENT		Applicant(s)	1.55.54.55	
MATION DISCLOSURE STATEMENT		IN DISCLOSURE STATEMENT	, · · · · · · · ·	vin P. BAKER , et al.	
			Filing Date:	Group Art Unit:	
(ı.	ise sev	eral sheets if necessary)	DECEMBER 11, 2001	1647	
			OTHER DOCUMENTS		
			hor, title, date, pertinent pages, e	etc.)	
				d –1beta in the Lung caused by Expression of	
	57.	Distinct mRNAs," J Biol Chem 279(2	24):25574-81 (2004) Abstract.		
	58.		Browth Factor Expression in Ova	rian Cancer," Acta Obstet Gynecol Scand Suppl	
	JU.	155:19-24 (1992) Abstract.			
	50			ancer: Quantitative Analysis of mRNA for	
	59.		ceptor Protein Expression and T	umor Pathology," <i>Breast Cancer Res. Treat.</i> -	
		92(2):175-86 (2005) Abstract.	nd Proteomic Analysis of the Effe	ect of CpG-ODN on Human THP-1 Monocytic	
	60.	Leukemia Cells," <i>Proteomics - <u>5(4)</u>:89</i>		to operable of Hamaii Thir -1 monocytic	
		Landmark, B.F., et al., "Cellular Locati	ion and Age-dependent Changes	of the regulatory Subunits of cAMP-dependent	
	61.	Protein Kinase in Rat Testis," J Repro			
	62.	Lassmann, S., et al., "Quantification o	f CK20 Gene and Protein Expres	sion in Colorectal Cancer by RT-PCR and	
	02.	Immunohistochemistry Reveals Inter-	and Intratumour Heterogeneity,	' J Pathol 198(2):198-206 (2002) Abstract.	
	63.			d Protein (MRP) mRNA and Protein in Normal	
		Peripheral Blood and Bone Marrow Ha			
	64.		othelial Growth Factor Enhances	Cardiac Allograft Arteriosclerosis," Circulation -	
		105(21):2524-30 (2002) Abstract.	a of Arashidania Asid Canalilia -	Fondom Poro Domoin Potoscium Channels in Pot	
	65.	Li, Z.B., et al., "Enhanced Expressions Experimental Acute Cerebral Ischemia		Tandem-Pore Domain Potassium Channels in Rat	
				Protein 27," Invest Ophthalmol Vis Sci	
	66.	44(3):1299-304 (2003) Abstract.	una the meachon of Heat-Silver	Trouble opinionion vio our	
	67		ssion of Tissue Plasminogen Ac	tivator and Plasminogen Activator Inhibitor Type	
	67.	2 in Dog Gingival Tissues with Progre			
	68.	Macabeo-Ong, M., et al., "Effect of Du	ration of Fixation on Quantitative	Reverse Transcription Polymerase Chain	
	UO.	Reaction Analyses," <u>15(9)</u> :979-87 (200			
	69.			ancer and in Dysplastic Lesions in Chronic	
		Pancreatitis," Am J Pathol 155(3):81			
ļ	70.		•	Yoked Hormone-Receptor Complex in HEK 293	
		Cells," J Mol Endocrinol 32(1):247-5		Expression Pattern in the Rat Uterine Epithelium	
	71.	During the Estrous Cycle," <i>Mol Repro</i>			
		Meoni, P., et al., "[3H]MK-801 Binding	and the mRNA for the NMDARIS	Subunit of the NMDA Receptor are Differentially	
	72.	Distributed in Human and Rat Forebra			
	Mezzano S.A. et al. "Overexpression of Chemokines Fibrogenic Cytokines and Myofibroblasts in Hum:				
	73.	Membranous Nephropathy," Kiney Int	t <u>57(1)</u> :147-58 (2000) Abstract.		
	74.		ne, G., et al., "Decreased Uncoupling Protein Expression and Intramyocytic Triglyceride Depletion in Formerly		
	/ 7.	Obese Subjects," Obes Res 11(5):6			
		Miralles, C.P., et al., "Differential Expr			
		GABAA/benzodiazepine Receptors,"			
	76.			senger Ribonucleic Acid are Present in the Reprod <u>61(3)</u> :776-84 (1999) Abstract.	
		Monaghan, P., et al., "The Alpha(v)bet			
	77.	Constitutively on the Epithelial Cells			
EXAMINER:		To the state of th	DATE CONSIDERE		
I			DATE OF HOLDERY		

		<u> </u>	
EXAMINER: Initial if citation considered	. whether or not the citation conf	forms with MPEP 609.	Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2226418 v1

PTO/SB/08 (2/92) Sheet 5 of 8 Form PTO-1449 Attorney's Docket No. Application Serial No. 10/015,499 39780-2830 P1C42 MATION DISCLOSURE STATEMENT Applicant(s) Kevin P. BAKER, et al. **Group Art Unit:** Filing Date: (use several sheets if necessary) **DECEMBER 11, 2001** 1647 OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Montuori, N., et al., "Urokinase-Mediated Posttranscriptional Regualtion of Urokinase-Receptor Expression in Non 78. Small Cell Lung Carcinoma," Int J Cancer - 105(3):353-60 (2003) Abstract. Munaut . C., et al., "Vascular Endothelial Growth Factor Expression Correlates with Matrix Metalloproteinases MT1-79. MMP, MMP-2 and MMP-9 in Human Glioblastomas," Int J Cancer - 106(6):848-55 (2003) Abstract. Nie, Y., et al., "DNA Hypermethylation is a Mechanism for Loss of Expression of the HLA Class I Genes in Human 80. Esophageal Squamous Cell Carcinomas," Carcinogenesis - 22(10):1615-23 (2001) Abstract. Nuciforo, P.G., et al., "Molecular and Immunohistochemical Analysis of HER2/neu Oncogene in Synovial Sarcoma," 81. Hum Pathol. - 34(7):639-45 (2003) Abstract. Oberringer, M., et al., "Differential Expression of Heat Shock Protein 70 in Well Healing and Chronic Human Wound 82. Tissue," Biochem Biophys Res Commun. - 214(3):1009-14 (1995) Abstract. Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Proteins Levels in Pairs of Non-83. invasive and Invasive Human Transitional Cell Carcincomas," Mol Cell Proteomics. - 1(1):37-45 (2002) Abstract. Orntoft, T.F., et al. "Genome-Wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-84. Invasive and Invasive Human Transitional Cell Carcinomas," Molecular & Cellular Proteomics - 1:37-45 (2002). Pachmann, K., et al., "Expression of bcr-abl mRNA in Individual Chronic Myelogenous Leukaemia Cells as determined 85. by in Situ Amplification," Br J. Haematol - 112(3):749-59 (2001) Abstract. Pairon, J.C., et al., "Cell Localization and Regulation of Expression of Cytochrome P450 1A1 and 2B1 in Rat Lung after 86. Induction with 3-Methylcholanthrene Using mRNA Hybridization and Immunohistochemistry," Am J Respir Cell Mol Biol. - 11(4):386-96 (1994) Abstract. Papotti, M., et al., "Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis 87. of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung," Diagn Mol Pathol. - 9(1):47-57 (2000) Abstract. Papotti, M., et al., "Expression of Somatostatin Receptor Types 1-5 in 81 Cases if Gastrointestinal and Pancreatic 88. Endocrine Tumors. A correlative Immunohistochemical and Reverse-Transcriptase Polymerase Chain Reaction Analysis," Virchows Arch. - 440(5):461-75 (2002) Abstract. Paredes, J., et al., "P-Cadherin Overexpression is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and 89. is Associated with CDH3 Promoter Hypomethylation," Clin Cancer Res. - 11(16):5869-77 (2005) Abstract. Politis, I., et al., "Mammary-Derived Growth Inhibitor Protein and Messenger Ribonucleic Acid Concentrations in 90. Different Physiological States of the Gland," J Dairy Sci. - 75(6):1423-9 (1992) Abstract. Preesman, A.H., et al., "T-Cell Receptor V Beta-family Usage in Primary Cutaneous and Primary Nodal T-cell non-91. Hodgkin's Lymphomas," J Invest Dermatol. - 99(5):587-93 (1992) Abstract. Pullig, O., et al., "Matrilin-3 in Human Articular Cartilage: Increased Expression in Osteoarthritis," Osteoarthritis 92. Cartilage - 10(4):253-63 (2002) Abstract. Rey, C., et al., "Up-regulation of Mitochondrial Peripheral Benzodiazepine Receptor Expression by Tumor Necrosis Factor Alpha in Testicular Leydig Cells. Possible Involvement in Cell Survival," Biochem Pharmacol. - 60(11):1636-46

Tissues: An Immunochemical Approach," Exp Cell Res 275(2):189-99 (2002) Abstract.			
96. Sedelies, K.A., et al., "Discordant Regulation of Granzyme H and Granzyme B Expression in Human Lymphocytes, Biol Chem 279(25):26581-7 (2004) Abstract.			
EXAMINE	R:	DATE CONSIDERED:	
FYAMINE	P: Initial	if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in	
		not considered. Include a copy of this form with next communication to applicant.	

Cervical Cancer," Am J. Clin Pathol. - 120(5):691-8 (2003) Abstract.

Rudlowski, C., et al., "GLUT1 Messenger RNA and Protein Induction Rrelates to the Malignant Transformation of

Sasaki, T., et al., "Expression and Distribution of Laminin Alpha1 and Alpha2 Chains in Embryonic and Adult Mouse

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2226418 v1

93.

94.

95.

(2000) Abstract.

AUG , S		•	PTO/SB/08 (2/92) Sheet 6 of 8	
2008	Form PTO-1449	Attorney's Docket No. 39780-2830 P1C42	Application Serial No. 10/015,499	
Form PTO-1449 FORMATION DISCLOSURE STATEMENT		Applicant(s)	AKER , et al.	
(use se	veral sheets if necessary)	Filing Date: DECEMBER 11, 2001	Group Art Unit: 1647	
	()ll	OTHER DOCUMENTS		
		uthor, title, date, pertinent pages, etc.) ssion Parallels its mRNA level in normal a	nd Malinant P Calle " Pland	
97.	104(9):2936-9 (2004) Abstract.			
98.		eterminations of the Steady Transcript Lev rmal Rat Tissues and the Malignant Tumor		
99.		Induced Activation of Activator Protein-1 in Keratinocyte Cell Line HaCat," <i>Photoche</i>		
100.	Localization," Am J. Physiol 267(4		-	
101.	Cyclooxgenase-2 Isoform in Culture	is Factor-Alpha Upregulates the Prostagla d Amnion WISH Cells," <i>J Interferon Cytok</i> i	ne Res <u>18(12)</u> :1039-44 (1998) Abstract.	
102.	Spike L at al. "Transcriptional Activity of Potent Clucocorticoids: Paleyance of Glucocorticard Pecentar Isoforms and			
103.	Splinter, P.L., et al., "Specific Inhibition of AQP1 Water Channels in Isolated Rat Intrahepatic Bile Duct Units by Small Interfering RNAs," J Biol Chem - 278(8):6268-74 (2003) Abstract.			
104.	Stearns, M.E., et al., "Type IV Collag Cancer Res 53(4):878-83 (1993) Ab	enase (M(r) 72,000) Expression in Human I estract.	Prostate: Benign and Malignant Tissue,"	
105.		d Detrusor III: Impact of Bladder Outlet Ob sion," <i>J Urol.</i> - <u>164(3Pt 2)</u> :1026-30 (2000) A		
106.	Strickland, I., et al., "TNF-Alpha and	IL-8 are Upregulated in the Epidermis of N lation and E-Selectin Expression," <i>J Inves</i>	ormal Human Skin after UVB Exposure:	
107.	Strutz, F., et al., "Basic Fibroblast G	rowth Factor Expression is Increased in Heroton," <i>Kidney Int.</i> - <u>57(4)</u> :1521-38 (2000)	uman Renal Fibrogenesis and May	
108.		rates Plasma MCP-1 Levels Leading to the		
109.	Takimoto, Y., et al., "Augmented Exp	pression of Neuronal Nitric Oxide Synthason Myocardial Infarction in Rats," <i>Circulation</i>		
110.	Telek, G., et al., "Differential Upregu	lation of Cellular Adhesion Molecules at th Surg Res 96(1):56-67 (2001) Abstract.		
111.	Timchanka L at al "Myotonic Dye	trophy: An Unstable CTG Repeat in a Prot	ein Kinase Gene," Semin Cell Biol	
112.			se Hepatoma Cell Line Hepa-1 by Various	
113.	Illimannova V et al "Polationshin	Between Cyclin D1 and p21 (Waf1/Cip1) D	uring Differentiation of Human Myeloid	
114.	Van Beers, E.H., et al., "Intestinal Ca Shows Species Differences and Mos 40 (1998) Abstract.	rbamoyl Phosphate Synthase I in Human a saic Expression in Duodenum of Both Spe	cies," J Histochem Cytochem <u>46(2)</u> :231-	
115.	Lines, Liver Metastases and Normal	n of Deoxycytidine Kinase in Leukaemic C Liver," <i>Eur J Cancer</i> - <u>39(5)</u> :691-7 (2003) A	bstract.	
116.	Waldherr R et al "Expression of C	Cytokines and Growth Factors in Human G	lomerulonephritides," <i>Pediatr Nephrol.</i> -	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conf	

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2226418 v1



Form PTO-1449 MATION DISCLOSURE STATEMENT		Attorney's Docket No.	Application Serial No. 10/015,499		
WATEN DICCLOSURE STATEMENT		39780-2830 P1C42 Applicant(s)	10/013,499		
NAME OF THE PROPERTY OF THE PR		Kevin P. BAKER, et al.			
·		Filing Date:	Group Art Unit:		
luca cav	eral sheets if necessary)	DECEMBER 11, 2001	1647		
[use sev		OTHER DOCUMENTS	1 1041		
		hor, title, date, pertinent pages, etc.)			
117.		ormation of the Human Endometrium is ass	ociated with Overexpression of		
117.		in," <i>Cancer Res <u>55(5)</u>:1168-75 (1995)</i> Abst			
118.		luman Soft Tissue Tumors Correlates with F	1		
		I and in Situ Hybridization Study," Cancer R			
119.	and Corresponding Prostatectomy Sp	rins and Catenins in Paired Tumor and Non- ecimens," <i>Urol Res.</i> - <u>28(5)</u> :308-15 (2000) Ab	ostract.		
		of Prostate-Specific Antigen Expression by f			
120.	Complex Formation Between Androget Gene in LNCaP Cells," Cancer Res 5	en Receptor and Steroid Receptor-binding C 57(4):714-9 (1997) Abstract.	onsensus in the Promoter of the PSA		
121.		Calcyclin in Human Melanocytic Lesions,"	Cancer Res <u>53(24)</u> :6061-6 (1993)		
		ation of the Cytochrome P450 3A Subfamily	in Humans." J Pharmacol Exp Ther.		
122.	311(2):728-35 (2004) Abstract.				
400		eased MARCKS Expression Correlates with	Ras Reversion but not with Mitogenic		
123.	Responsiveness" Oncogene - 8(3):75	5-60 (1993) Abstract.			
124.	Zhong, W., et al., "Expression of Supe Radic Biol Med 27(11-12):1334-45 (1	roxide Dismutases, Catalase, and Glutathio	ne Peroxidase in Glioma Cells," <i>Free</i>		
125.	Xi, L., et al., "Expression of Human Te	lomerase Reverse Transcriptase in Cervix C	ancer and its Significance,"		
	Zhonghua Fu Chan Ke Za Zhi - <u>40(6)</u> :4	07-10 (2005) Abstract.			
400	Albarta D. et al. Malagular Biology	64h - Call (2m ad 4004) Call 2m at 452 Figure	0.2 of Coll 2m Coll 2m of 402		
126.		f the Cell (3rd ed. 1994) Cell 3rd at 453 Figure			
127.	Cell 4th Cell 4th at 364 Cell 4th at 379	f the Cell (4 rd ed.) In Cell 4 th , Figure 6-3 on pa			
128.		oma Cell Lines and Normal Thyrocytes: Exp Metalloproteinase Inhibitor-` Messenger-RI			
120.	(1997)	metanoproteinase illinbitor- messeriger-tu	The state of the s		
400		on and Overexpression in Hematological M	alignancies Occur Mainly in Mantle		
129.	Cell Lymphomas," Cancer Research -				
130.		predict survival of patients with lung adeno	carcinoma," <i>Nature Biomedicine -</i>		
130.	<u>98(6)</u> :816-824 (2002)				
131.		Yeast Proteome," Molecular and Cellular Bio	· · · · · · · · · · · · · · · · · · ·		
132.	Gnatenko, D.V., et al., "Transcript Prof Expression," Blood - 101(6):2285-2293	filing of Human Platelets Using Microarray a 3 (2003)	nd Serial Analysis of Gene		
Greenbaum, D., et al., "Analysis of mR		NA Expression and Protein Abundance Dat			
133.		ellular Population of Proteins and Transcrip	ots," <i>BioinformaticsI - <u>18(4)</u>:585-496</i>		
	(2002)				
424	Gromova, I., et al., "Protein Abundancy and mRNA Levels of the Adipocyte-Type Fatty Acid Binding Protein Correlate 134. Non-Invasive and Invasive Bladder Transitional Cell Carcinomas," International Journal of Oncology - 13(2) 6 pages				
134.	Non-invasive and invasive Bladder I in (1998)	ansidonal Cell Carcinomas," <i>international Je</i>	ournal of Oncology - 13(2) o pages		
		S2 Gene in Breast Tissues Assessed by nS2	2-mRNA Analysis and pS2-Protein		
Hähnel, E., et al., "Expression of the pS2 Gene in Breast Tissues Assessed by pS2-mRNA Analysis and pS2-Protein					

EXAMINER:	DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation of conformance and not considered. Include a copy of this form with ne		Į.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2226418 v1

Sheet 8 of 8 Application Serial No. Form PTO-1449 Attorney's Docket No. 39780-2830 P1C42 10/015,499 **ATION DISCLOSURE STATEMENT** Applicant(s) Kevin P. BAKER, et al. **Group Art Unit:** Filing Date: **DECEMBER 11, 2001** 1647 (use several sheets if necessary) OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Hirsch, F.R., et al., "Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology," Clinical Cancer Research - 7:5-22 (2001) Holten-Andersen, M.D., et al., "Localization of Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) in Human Colorectal 137. Adenoma and Adenocarcinoma," Int. J. Cancerl - 113:198-206 (2005) Janssens, N., et al., "Alteration of Frizzled Expression in Renal Cell Carcinoma," Tumor Biology - 25:161-171 (2004) 138. Kammori, M., et al., "Expression of Human Telomerase Reverse Transcriptase Gene and Protein, and of Estrogen and Progesterone Receptors, in Breast Tumors: Preliminary Data from Neo-Adjuvant Chemotherapy", International Journal of Oncology - 27(5) (2005) Kuo, C.C., et al., "A Transcriptomic and Proteomic Analysis of the Effect of CpG-ODN on Human THP-1 Monocytic 140. Leukemia Cells," Proteomics - 5:894-906 (2005) Lewin, B., Genes VI (1997 Genes VI at 847-848 141. Meric, F., et al., "Translation initiation in Cancer: A Novel Target for Therapy," Molecular Cancer Therapeutics - 1:971-142. 979 (2002) Munaut, C., et al., "Vascular Endothelial Growth Factor Expression Correlates With Matrix Metalloproteinases MT1-NMP, 143. MNP-2 and NMP-9 in Human Glioblastomas," Int. J. Cancer - 106:848-855 (2003) Maruyama, H., et al., "Id-1 and Id-2 are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic 144. Pancreatitis," American Journal of Pathology - 155(3):815-822 (1999) Nuciforo, P. G., et al., "Molecular and Immunohistochemical Analysis of HER2/neu Oncogene in Synovial Sarcoma," 145. Human Pathology - 34(7):639-645 (2003) Papotti, M., et al., "Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung," Diagnostic Molecular Pathology - 9(1):47-57 146. Walmer, D. K., et al., "Malignant Transformation of the Human Endometrium is Associated with Overexpression of 147. Lactoferrin Messenger RNA and Protein," Cancer Research - 55(5):1168-1174 (1995) Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and non-Neoplastic Primary Prostate Cultures 148. and Corresponding Prostatectomy Specimens," Urol Resl - 28:308-315 (2000) Zhigang, Z., et al., "Prostate Stem Cell Antigen (PSCA) Express in Human Prostate Cancer Tissues and its Potential 149. Role in Prostate Carinogenesis and Progession of Prostate Cancer," World Journal of Surgical Oncology - 2-13 (2004)

EXAMINER:	DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2226418 v1